With this, Apollo Hospitals' stake in its subsidiary will rise to 99.42%. The transaction will be at ₹301.09 per share.
AHLL's turnover in the financial year 2025 was at ₹1,553.5 crore. The company said the acquisition will allow for a sharper allocation of capital and greater focus on selected high-potential segments.
Apollo to set up oncology facility in Gurugram
On another note, Apollo Hospitals is also setting up a comprehensive oncology facility in Gurugram for ₹573 crore. It will be part of a 500-bed hospital in Gurugram and is scheduled to be completed in the financial year 2029.
The facility will include the precision cancer treatment tech — Single Gantry Proton Proteus One System. This will mark the third proton therapy installation in India after the previous ones in Chennai and Hyderabad.
Apollo Hospitals said it is looking to double oncology therapy to ₹5,000 crore within the next three to four years.
Nomura sees 13% downside
Brokerage firm Nomura has a "neutral" rating on Apollo Hospitals with a target price of ₹6,856 per share, a 12.8% downside from its previous closing price of ₹7,864.5 apiece.
It said AHLL will become Apollo Hospitals' 100% subsidiary post the acquisition, which will also lead to IFC's exit from the firm after eight years.
With Apollo Hospitals now owning 99.42% in AHLL and the balance in ESOP pool, Nomura said it believes that just like its pharma business, the company might be considering a separate listing of AHLL as well.
A full-ownership of AHEL should result in greater flexibility with respect to capital allocation and better operational synergies for AHLL, it added.
Of the 32 analysts that have coverage on the stock, 28 have a "buy" rating, three have a "hold" rating and one has a "sell" rating.
Shares of Apollo Hospitals ended the previous session 0.19% lower. The stock has gained 25.9% in the last six months.
Also Read: Vedanta shares head into an important week with two triggers in sight
